Docetaxel and exisulind in hormone-refractory prostate cancer

• 31 August 2001
• journal article
• clinical trial
• Published by Elsevier in Seminars in Oncology
• Vol. 28, 56-61
• https://doi.org/10.1016/s0093-7754(01)90156-3

Abstract

Keywords

• SURVIVAL
• MODELS
• REFRACTORY
• DOCETAXEL
• HORMONE
• PROSTATE
• PSA
• ANTIGEN
• EXISULIND
• HRPC